Vistagen Therapeutics (MEX:VTGN) Cyclically Adjusted FCF per Share: MXN-246.63 (As of Mar. 2026)


MEX:VTGN Vistagen Therapeutics Inc MEX:VTGN
29 GF Score
Price MXN10.65
GF Value MXN93.91
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Cyclically Adjusted FCF per Share?

Vistagen Therapeutics MEX:VTGN 29 Cyclically Adjusted FCF per Share is MXN-246.63 as of Mar. 2026. GuruFocus rates MEX:VTGN with a GF Score™ of 29/100 and a GF Value™ of MXN93.91. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Vistagen Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was MXN-6.901. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN-246.63 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 29.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 25.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Vistagen Therapeutics was 29.30% per year. The lowest was 2.70% per year. And the median was 18.05% per year.

As of today (2026-07-11), Vistagen Therapeutics's current stock price is MXN10.65. Vistagen Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was MXN-246.63. Vistagen Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Vistagen Therapeutics  (MEX:VTGN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Vistagen Therapeutics Cyclically Adjusted FCF per Share Related Terms


Vistagen Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Cyclically Adjusted FCF per Share Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -246.63

Vistagen Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -246.63

MEX:VTGN vs PSTV, KYNB, TVGN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Vistagen Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistagen Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


MEX:VTGN
29GF Score
Vistagen Therapeutics Inc MEX:VTGN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vistagen Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-6.901/330.2130*330.2130
=-6.901

Current CPI (Mar. 2026) = 330.2130.

Vistagen Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -182.000 241.018 -249.354
201609 -159.302 241.428 -217.885
201612 -154.961 241.432 -211.944
201703 -100.269 243.801 -135.808
201706 -128.153 244.955 -172.757
201709 -103.170 246.819 -138.029
201712 -103.713 246.524 -138.921
201803 -61.921 249.554 -81.935
201806 -81.317 251.989 -106.560
201809 -88.245 252.439 -115.432
201812 -74.989 251.233 -98.563
201903 -59.243 254.202 -76.958
201906 -64.359 256.143 -82.970
201909 -57.476 256.759 -73.919
201912 -56.095 256.974 -72.082
202003 -38.542 258.115 -49.308
202006 -37.867 257.797 -48.504
202009 9.919 260.280 12.584
202012 -36.715 260.474 -46.545
202103 -17.932 264.877 -22.355
202106 -19.881 271.696 -24.163
202109 -36.715 274.310 -44.197
202112 -36.642 278.802 -43.399
202203 -45.102 287.504 -51.802
202206 -47.156 296.311 -52.551
202209 -47.749 296.808 -53.123
202212 -28.123 296.797 -31.289
202303 -18.816 301.836 -20.585
202306 -18.438 305.109 -19.955
202309 -10.736 307.789 -11.518
202312 -2.742 306.746 -2.952
202403 -4.290 312.332 -4.536
202406 -6.532 314.175 -6.865
202409 -7.037 315.301 -7.370
202412 -6.981 315.605 -7.304
202503 -6.580 319.799 -6.794
202506 -11.152 322.561 -11.417
202509 -7.091 324.800 -7.209
202512 -7.528 324.054 -7.671
202603 -6.901 330.213 -6.901

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN-246.63 mean?
Vistagen Therapeutics (MEX:VTGN) has a Cyclically Adjusted FCF per Share of MXN-246.63 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vistagen Therapeutics and its competitors.
Is Vistagen Therapeutics' Cyclically Adjusted FCF per Share too high?
Vistagen Therapeutics' current Cyclically Adjusted FCF per Share is MXN-246.63. Overall, Vistagen Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Cyclically Adjusted FCF per Share compare to PSTV and KYNB?
Vistagen Therapeutics' Cyclically Adjusted FCF per Share of MXN-246.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Cyclically Adjusted FCF per Share is MXN-246.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current Cyclically Adjusted FCF per Share of MXN-246.63. The stock's GF Value™ is MXN93.91, compared to a current price of MXN10.65 — trading 88.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN-246.63. Vistagen Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current Cyclically Adjusted FCF per Share is MXN-246.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (MEX:VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of MXN10.65 is trading 88.7% below its estimated GF Value™ of MXN93.91.

Key valuation signals for MEX:VTGN:

  • Cyclically Adjusted FCF per Share: MXN-246.63
  • GF Value™: MXN93.91 vs. price of MXN10.65 (88.7% below fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the MEX:VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistagen Therapeutics Business Description

Other Exchanges VTGN:USA
Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
29GF Score

Get the complete analysis for MEX:VTGN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN10.65
Price
MXN93.91
GF Value